{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:16:37Z","timestamp":1758402997630},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40265-015-0366-1","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T06:09:15Z","timestamp":1426054155000},"page":"533-542","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg L.","family":"Plosker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"366_CR1","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1\u2013130.","journal-title":"Kidney Int Suppl"},{"key":"366_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2369-14-153","volume":"14","author":"A Covic","year":"2013","unstructured":"Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153.","journal-title":"BMC Nephrol."},{"issue":"2","key":"366_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ckj\/sfs173","volume":"6","author":"M Ketteler","year":"2013","unstructured":"Ketteler M, Wuthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J. 2013;6(2):128\u201336.","journal-title":"Clin Kidney J."},{"key":"366_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/IJNRD.S35632","volume":"6","author":"A Cupisti","year":"2013","unstructured":"Cupisti A, Gallieni M, Rizzo MA, et al. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193\u2013205.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"366_CR5","unstructured":"National Institute for Health and Care Excellence. Hyperphosphataemia in chronic kidney disease: management of hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease (NICE clinical guideline 157). 2013. http:\/\/www.nice.org.uk . Accessed 23 Feb 2015."},{"issue":"4","key":"366_CR6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2215\/CJN.00560206","volume":"1","author":"SM Moe","year":"2006","unstructured":"Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697\u2013703.","journal-title":"Clin J Am Soc Nephrol."},{"key":"366_CR7","unstructured":"Fresenius Medical Care North America. Velphoro (sucroferric oxyhydroxide) chewable tablet for oral use: US prescribing information. 2014. http:\/\/www.velphoro.us . Accessed 23 Feb 2015."},{"key":"366_CR8","unstructured":"Vifor Fresenius Medical Care Renal Pharma France. Velphoro 500\u00a0mg chewable tablets: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 23 Feb 2015."},{"key":"366_CR9","unstructured":"Kissei Pharmaceutical Co. Ltd. New drug application submitted for \u201cPA21 (development code)\u201d for treatment of hyperphosphatemia [media release]. 19 Nov 2014. http:\/\/kissei.co.jp\/e_contents ."},{"issue":"04","key":"366_CR10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","volume":"81","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm M, Gaillard S, Rakov V, et al. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(04):251\u20138.","journal-title":"Clin Nephrol"},{"issue":"4","key":"366_CR11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ndt\/14.4.863","volume":"14","author":"O Hergesell","year":"1999","unstructured":"Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14(4):863\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"366_CR12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3109\/03639045.2013.838583","volume":"40","author":"M Lanz","year":"2014","unstructured":"Lanz M, Baldischweiler J, Kriwet B, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623\u201331.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"366_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","volume":"74","author":"P Geisser","year":"2010","unstructured":"Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74(1):4\u201311.","journal-title":"Clin Nephrol"},{"key":"366_CR14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638\u201347.","journal-title":"Kidney Int"},{"key":"366_CR15","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015. doi: 10.1093\/ndt\/gfv006 .","journal-title":"Nephrol Dial Transplant"},{"key":"366_CR16","unstructured":"Sprague SM, Covic A, Floege J, et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract plus poster]. In: National Kidney Foundation 2014 Spring Clinical Meeting. 2014."},{"issue":"6","key":"366_CR17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40620-014-0080-1","volume":"27","author":"E Chong","year":"2014","unstructured":"Chong E, Kalia V, Willsie S, et al. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol. 2014;27(6):659\u201366.","journal-title":"J Nephrol."},{"key":"366_CR18","unstructured":"Levesque V, Chong EMF, Moneuse P. Post-hoc analysis of pharmacodynamic interaction of PA21 with statins in a phase 3 study of PA21 in dialysis patients with hyperphosphatemia [abstract no. SA-PO568]. In: American Society of Nephrology Kidney Week 2013. 2013."},{"issue":"Suppl 3","key":"366_CR19","first-page":"iii157","volume":"29","author":"J Floege","year":"2014","unstructured":"Floege J, Botha J, Chong E, et al. PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract no. SP257]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii157.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"366_CR20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","volume":"8","author":"RP Wuthrich","year":"2013","unstructured":"Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):280\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"key":"366_CR21","unstructured":"Vifor Inc. A phase 3 study to investigate the safety and efficacy of PA21, a phosphate binder, in dialysis patients [ClinicalTrials.gov identifier NCT01324128]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ . Accessed 23 Feb 2015."},{"key":"366_CR22","unstructured":"Covic AC, Floege J, Ketteler M, et al. Efficacy and safety of PA21, a novel iron-based phosphate binder in CKD patients on peritoneal- and hemodialysis [abstract]. In: 15th Congress of the International Society of Peritoneal Dialysis. 2014."},{"key":"366_CR23","unstructured":"Floege J. Efficacy and safety of the novel iron-based phosphate binder PA21 in peritoneal- and hemodialysis-dependent CKD patients [abstract plus poster]. In: 11th European Peritoneal Dialysis Meeting. 2013."},{"issue":"Suppl 3","key":"366_CR24","first-page":"iii153","volume":"29","author":"A Covic","year":"2014","unstructured":"Covic A, Ketteler M, Rastogi A, et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract no. SP245]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii153.","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"366_CR25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40265-013-0054-y","volume":"73","author":"F Malberti","year":"2013","unstructured":"Malberti F. Hyperphosphataemia: treatment options. Drugs. 2013;73(7):673\u201388.","journal-title":"Drugs."},{"issue":"8","key":"366_CR26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-014-0224-6","volume":"74","author":"D Nastou","year":"2014","unstructured":"Nastou D, Fernandez-Fernandez B, Elewa U, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74(8):863\u201377.","journal-title":"Drugs."},{"issue":"6","key":"366_CR27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089\u201396.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"366_CR28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","volume":"29","author":"S Wang","year":"2014","unstructured":"Wang S, Alfieri T, Ramakrishnan K, et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"366_CR29","first-page":"iii271","volume":"29","author":"FS Gutzwiller","year":"2014","unstructured":"Gutzwiller FS, Braunhofer PG, Szucs TD, et al. Health economic evaluation of non-calcium-based phosphate binders in Scotland [abstract no. SP596]. Nephrol Dial Transplant. 2014;29(Suppl 3):iii271.","journal-title":"Nephrol Dial Transplant."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0366-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0366-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0366-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:41Z","timestamp":1559490101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0366-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0366-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}